Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Liabilities (2016 - 2025)

OptimizeRx's Total Liabilities history spans 16 years, with the latest figure at $48.1 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 5.27% year-over-year to $48.1 million; the TTM value through Sep 2025 reached $48.1 million, down 5.27%, while the annual FY2024 figure was $54.2 million, 4.67% down from the prior year.
  • Total Liabilities for Q3 2025 was $48.1 million at OptimizeRx, down from $50.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $56.8 million in Q4 2023 and bottomed at $5.5 million in Q2 2023.
  • The 5-year median for Total Liabilities is $8.5 million (2022), against an average of $26.1 million.
  • The largest annual shift saw Total Liabilities tumbled 54.52% in 2021 before it soared 841.25% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $9.6 million in 2021, then fell by 11.09% to $8.5 million in 2022, then soared by 565.32% to $56.8 million in 2023, then decreased by 4.67% to $54.2 million in 2024, then decreased by 11.28% to $48.1 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Total Liabilities are $48.1 million (Q3 2025), $50.0 million (Q2 2025), and $51.5 million (Q1 2025).